ENK et al. applied interleukin-2 (IL-2) inhalation therapy to patients with pulmonary metastatic melanoma by transferring cytokines to the tumor site, which reduced the toxicity associated with systemic IL-2 administration and achieved good efficacy17. Here, IL2 is linked to metastatic melanoma.